StreetAlpha.app
Home › Stocks › MAZE

Maze Therapeutics, Inc. (MAZE)

Healthcare
$32.87
▼ −3.04%
LAST CLOSE · NOV 17

Maze Therapeutics develops small molecule drugs for kidney and metabolic diseases and has no approved products yet. It last closed at $32.87 on Nov 17, down 3.04% on the day. The average 12-month price target from 4 analysts is $56.25 (+71.1% from the last close), with a high of $75.00 and a low of $49.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $808K, the largest $808K.

AI Auto Pilots
Is MAZE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$151.5M
EPS (diluted)
−$2.62
Free cash flow
−$115.3M
Valuation
Market cap
$1.8B
54.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$154.2M
At Sep 30
Debt
$39.1M
At Sep 30
Shareholder equity
$428.5M
Shares outstanding
54.7M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $52.2M$52.2MFY2024FY2025: −$131.1M−$131.1MFY2025

From MAZE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MAZE in the past 90 days
Average 12-month target
$56.25
▲ 71.1% upside

Based on 4 analysts who set a price target on MAZE in the past 90 days. The average target is $56.25, with a high of $75.00 and a low of $49.00, compared with the last close of $32.87.

Low $49.00Avg $56.25High $75.00
Blue marker: last close $32.87
Highest target$75.00
Average target$56.25
Lowest target$49.00
Latest rating changes
JP MorganMaintained
Nov 11Buy$51
WedbushTarget raised
Nov 10Buy$48 → $49
Canaccord GenuityInitiated
Oct 19Buy$75
CitigroupInitiated
Sep 23Buy$50
WedbushReiterated
Sep 23Buy$48
DateFirmActionRatingPrice target
Nov 11JP MorganMaintainedBuy$51
Nov 10WedbushTarget raisedBuy$48 → $49
Oct 19Canaccord GenuityInitiatedBuy$75
Sep 23CitigroupInitiatedBuy$50
Sep 23WedbushReiteratedBuy$48
Loading…

Technical Analysis

MAZE · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 5% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 53). The nearest support is the Pivot S1 at $31.96, and the nearest resistance the 20 day average at $33.02.

Short trendBullish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 5.8%/day
Key levels
$53.6552 week high+63.2%
$33.98Pivot R1+3.4%
$33.19Swing high (Oct 21)+1.0%
$33.06Pivot+0.6%
$33.0220 day average+0.5%
$32.87Last close
$31.96Pivot S1−2.8%
$31.25200 day average−4.9%
$29.80Swing low (Nov 2)−9.3%
$28.9750 day average−11.9%
$28.78100 day average−12.4%
$21.9552 week low−33.2%
Indicators
RSI (14)53.35Middle of its rangeNeutral
MACD1.56Below its signal lineBearish
Stochastic51.3Middle of its rangeNeutral
ADX (14)30.1Trending up
Williams %R-59.7Oversold below −80, overbought above −20Neutral
CCI (20)3.3Oversold below −100, overbought above 100Neutral
Rate of change+1.9%Change over 10 sessionsBullish
ATR (14)$1.91Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for MAZE

What happened before

See how MAZE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in MAZE in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$808K
Largest print
$808K
Loading…

MAZE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲82 buying vs 64 selling
  • ▲Held by funds +3.3 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158162−2.5%
In funds' top 1078−12.5%
Held by funds110.4%107.0%+3.3 pts
New / increased19 / 6337 / 67−21.2%
Reduced / sold out40 / 2436 / 39−14.7%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MAZE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MAZE is in one of them and how their past MAZE trades turned out.

MAZE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MAZE in an article yet. Here's the latest on the wider market.

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company based in South San Francisco, California. It develops small molecule oral drugs for patients with kidney and metabolic diseases, using human genetic data to identify targets and guide development. Its most advanced candidate is in clinical trials for a genetically defined form of chronic kidney disease, and a second candidate is being prepared for trials in a metabolic disorder and chronic kidney disease. The company has no approved products, and it has partnered some of its programs with other drugmakers.

Headquarters
South San Francisco, CA